intractable partial onset epilepsy
Neurology · 2017–2019
4decisions
2medicines
3carried consumer input
0individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| brivaracetam Extension of existing listing for treatment of intractable partial onset epileptic seizures in combination with anti-epileptic drugs to include patients aged… | Nov 2019 | Recommended with restriction | input received |
| lacosamide Extension of existing listing for treatment of intractable partial onset epileptic seizures in combination with two or more anti-epileptic drugs in children… | Nov 2018 | Recommended with restriction | input received |
| brivaracetam Add-on therapy for the treatment of intractable partial onset epileptic seizures in patients aged 16 years or older, in combination with two or more… | Mar 2017 | Not recommended | input received |
| brivaracetam Intractable partial onset epileptic seizures in patients aged 16 years or older with epilepsy not adequately controlled on at least three anti-epileptic drugs… | Nov 2017 | Recommended with restriction | none received |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 3 of 4 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.